| 1 | New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy. 2021;9:61 doi: 10.1002/ccr3.3418 |
| 2 | Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. 2019;27:383 doi: 10.1007/s00520-018-4501-x |
| 3 | Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. 2019;127:117 doi: 10.1016/j.oooo.2018.09.008 |
| 4 | Risk factors for medication-related osteonecrosis of the jaws: A systematic review. 2018;24:527 doi: 10.1111/odi.12708 |
| 5 | Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. 2018;125:440 doi: 10.1016/j.oooo.2018.02.003 |
| 6 | Alveolar bone histological necrosis observed prior to extractions in patients, who received bone‐targeting agents. 2020;26:955 doi: 10.1111/odi.13294 |
| 7 | Medication-related osteonecrosis of the jaw – a scoping review. 2022;333:1291 doi: 10.1097/FAD.0000000000000061 |
Journal of Cancer Metastasis and Treatment
